4.7 Article

A Medicinal Chemistry Perspective for Targeting Histone H3 Lysine-79 Methyltransferase DOT1 L

Journal

JOURNAL OF MEDICINAL CHEMISTRY
Volume 56, Issue 22, Pages 8972-8983

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/jm4007752

Keywords

-

Funding

  1. Keck Center of the Gulf Coast Consortia
  2. Pharmacological Sciences Training Program, National Institute of General Medical Sciences (NIGMS) [T32GM089657]

Ask authors/readers for more resources

Histone H3 lysine79 (H3K79) methyltransferase DOT1L plays an important role in the activation and maintenance of gene transcription. It is essential for embryonic development as well as normal functions of the hematopoietic system, heart, and kidney in adults. DOT1L has been found to be a drug target for acute leukemia with mixed lineage leukemia (MLL) gene translocations. The rearranged onco-MLL can recruit DOT1L, causing aberrant H3K79 methylation, overexpression of leukemia relevant genes, and eventually leukemogenesis. Potent DOT1L inhibitors possess selective activity against this type of leukemia in cell-based and animal studies, with the most advanced compound being in clinical trials. In the medicinal chemistry point of view, we review the biochemistry, cancer biology, and current inhibitors of DOT1L, as well as biophysical (including X-ray crystallographic) investigation of DOT1L inhibitor interactions. Potential future directions in the context of drug discovery and development targeting DOT1L are discussed.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available